Networking Day

1
Networking Day 1 BioMedical Materials
Program Eindhoven, December 3, 2007
2
Agenda
A. BioMedical Materials (Emiel Staring) B.
Research agenda and call for proposals (Frank
Baaijens) C. Financial guidelines for
participants (Frank Baaijens) D. IP ground
rules (Emiel Staring) E. Questions F.
Networking event
1330 1345 1415 1430 1445 1500
3
A. BioMedical Materials (Emiel Staring)
4
During todays networking meeting, you will learn
about the BMM program and discuss future project
proposals
Information about the BMM program

• Structure and objectives of the BMM program
• A preview of
• Call for proposals
• Financial model
• IP framework

5
BMM is a strong public-private partnership
connecting key players active in the field of
biomedical materials
Total budget 90 m for a 5 year program
6
BMM strives for breakthroughs in biomedical
materials and a strengthened Dutch knowledge
infrastructure
2007
2008
2009
2010
2012
2011
BMM Vision and Ambition

• Biomedical materials will play a key role in
  enabling medical breakthroughs in healthcare
  which are essential to meet the growing need for
  advanced medical treatment
• BMM will strive to create a strong Dutch
  knowledge infrastructure
• Industry and knowledge centers cooperate in
  multidisciplinary research projects
• 150 new research positions (50 outflow to
  industry)
• Some 300 publications and patents
• Results Scientific, clinical, economic value
  creation

Business plan is available as PDF downloadable
on the website
7
Since Prinsjesdag, several meetings with the
Executive Board and the government have been held
BMM PLANNING 2007
September
October
November
December
18
3
18
25
31
14
Principal Meetings Milestones
Executive Board meeting
Prinsjesdag formal Approval
Meeting with Senter Novem
2nd EB meeting
Meeting with government
Network event

• MT installed
• Network event planned

• Network opportunity for partners to form project
  consortia

• Approval of key documents and processes

• Docs, facts figures for start-up

Meeting agendas
High
Meeting/Milestone
8
In January, the call for proposals will open and
in June we expect to wrap up the review process
BMM PLANNING 2008
January
February
March
31
7
21
17
14
Principal Meetings Milestones
Supervisory Board meeting
Networking Day 2 3rd Executive Board Call for
proposals
Call for proposals closes
Maria vd Hoeven visits BMM
Peer review begins
April
May
June
26
13
28-1
Principal Meetings Milestones
ISAB review begins
ISAB review begins
EB meeting presentation of draft portfolio
World Biomaterials Congress
Note All dates regarding the call for proposals
and review are provisional
High
Meeting/Milestone
9
The BMM governance boards represent the interests
of all partners and will steer the program
accordingly
Supervisory Board (SB)
Executive Board (EB)

• S. Hartig (Ind.)
• H. van den Berg (Ind.)
• F. Pieper (SME)
• J. Feijen (Acad.)

• S. Poppema (Acad.)
• H. Hillen (Acad.)
• T. Colijn (Indep.)

Who Representative of all partners that have
signed a letter of commitment or intent What
The strategic direction of the RD program
Approval of the RD program, annual operating
plan and budget
SB
I S A B
EB
MT

• B. Löwenberg (NL)
• M. Yacoub (UK)
• A. Caplan (USA)
• K. Wooley (USA)
• D. Tirrell (USA)

• F. Lameire (BEL)
• ....

Who Managing Director (E. Staring), Scientific
Director (F. Baaijens) What Represent and
manage BMM on a day-to-day basis
Recommends research programs to the MT
Management Team (MT)
International Scientific Advisory Board (ISAB)
10
All governance boards are involved in the
evaluation of project proposals
Supervisory Board
1
11
Mandates EB (within agreed framework)
Presents to SB
10
Approves
Executive Board
International Scientific Advisory Board
7
Presents to MT
2
9
8
Requests research plan
Iterates
Presents to EB
The field
6
Management Team
3
Request for advice
Call for proposals (clearly stating all
evaluation criteria)
5
Consolidates into research plan
4
Iterates -gt Submits
Organizes peer review
11
Research agenda and call for proposals (Frank
Baaijens)
12
The research agenda of the BMM program is
designed as a four step process involving all BMM
partners
1
2
3
4
Five Technology Platform workshops
Focal areas are selected
Focal areas are combined into research lines
13 project proposals are detailed
November 2006 Strategic research committee and
working group prepare focal areas for government
presentation
September 2006 Focal areas are defined partners
get to know each other
April 2007 An appendix of example projects is
compiled for the Commissie van Wijzen which
offers insight into the direction of the BMM
research agenda and the quality of its partners
13
The BMM research agenda consists of five research
lines selected for their economic and clinical
relevance
Selection criteria for research lines

• Clinical demand
• Economic relevance
• Existing knowledge base in the Netherlands
• Potential for biomedical materials breakthroughs
• Critical mass
• Coherence

14
Each research line is further pinpointed to one
or more focal areas
15
The quality of the program will be guaranteed in
the coming months through an open call for
proposals

• The call for proposals is open to all national
  knowledge centers, industrial parties with a
  research location in the Netherlands and charity
  foundations
• The industrial and academic parties must form
  consortia, and consortia will propose research
  projects
• The best research projects and participants will
  be selected through an interactive peer review
  and consultation with the International
  Scientific Advisory Board
• The ISAB will rank projects per research line and
  the EB will approve the final portfolio
• The approval of a proposal does not guarantee
  that the full budget will be granted
• The call for proposals is set to open on January
  14, 2008 with a deadline in March 2008 dates
  are provisional and subject to government approval

16
BMM will divide the EUR 90 m budget over two
separate calls to further increase the quality of
the program
17
Project proposals must meet eight procedural and
financial criteria to compete in the first call

• In each project, at least one academic and one
  industrial partner must participate to ensure
  direct interaction between these two partner
  types
• A project should comprise a multidisciplinary
  research effort, including at least a clinician
  and a technologist
• A minimum of three different partners is required
  in order to strengthen network formation
• The size of a project needs to be EUR 2-8 m for
  the lifetime of a project (maximum 5 years) and
  the end date of the project should be no later
  than end of year 2012
• The project should have quid-pro-quo funding from
  Industry and Academic sources
• The project must fit directly in one (or more) of
  the focal areas (which make up the research
  lines)
• The project should be of the highest scientific
  quality, to be judged by peer review
• Each project must have a clear clinical and
  economic value creation potential

18
All proposals must score at least "good" on
scientific quality, economic and clinical value
creation

• Scientific quality
• Relevance
• Innovativeness
• Research method
• Coherence
• Strength of the consortium
• ...

Scientific quality

• Economic value creation
• Translation into products and/or services
• Impact on economy and/or Dutch competitiveness
• Patentable results
• ...

Evaluation Criteria

• Clinical value creation
• Pre-clinical objectives
• Plans for clinical implementation
• ...

Clinical value creation
Economic value creation
Excellent
Very good
Good
Below average
Poor
Scale on which project will be ranked
19
Call preview

• Project description
• Consortium
• Economic value creation
• Clinical value creation

20
Call preview (subject to approval)

• 1. Project description
• Clinical need and problem definition (max 3 A4)
• Background
• Current international status
• Objectives, including clinical and technological
  breakthroughs
• Plan of investigation
• Preliminary results
• Working plan describe work packages (max 10 A4)
• Clinical and technological hurdles (max 1 A4)
• Table with overview of WPs and researchers (max
  1 A4)
• Gantt chart, including milestones and
  deliverables (max 1 A4)
• Existing infrastructure (max 1 A4)
• Motivation for investments (max 1 A4)
• Relation to other research in consortium (max 1
  A4)

21
C. Financial guidelines for participants (Frank
Baaijens)
22
All cash flows will run through the BMM program
112 funding scheme
Government
Industry1)
Academia
EUR 33 m In kind
EUR 12 m Cash
EUR 45 m Cash
BMM EUR 90 m
Hire of personnel (incl. use of materials and
infrastructure)
Investments
GA
Industry
Third parties
Academia
1) Charity foundations will be counted as
Industry
23
Key Objective Strengthen research infrastructure
for Biomedical Materials

• Increase the number and quality of researchers,
  both in industry and academia
• Increase interaction between industry and
  academia
• "Cash for Brains" Cash contribution is
  primarily translated into NEW personnel
• Simple, transparent and fair matching structure
• Four types of research costs are covered
• Cost of personnel
• Cost of materials services
• Cost of usage of existing equipment and
  infrastructure
• Investments

24
Invoices will include actual cost of wages and
mark-ups for overhead, use of materials and other
expenses
Actual cost of wages (Gross salary, social
security contribution, pension charges)

• Supervision, support and counseling
• Use of researchers ? 0.2 FTE
• Usual courses and training

EUR 15.000 fixed fee

• Use of laboratory equipment
• Use of general infrastructure
• Overhead

50 overhead1) (to cover general cost, overhead)

• Materials, consumables, small equipment
• Travel expenses, costs of conference visits

EUR 25.000 bench fee
1) These are overhead costs made by the employer,
not BMM overhead
25
EXAMPLE
Example PhD Student
New PhD, paid for by BMM
In kind
Full tariff
To be paid to partners by BMM
In-kind contribution of partners
40.000
40.000
Actual cost of wages
15.000
15.000
Fixed fee Supervision Support
27.500
27.500
50 Overhead
25.000
25.000
Bench fee
107.500
65.000
42.500
26
Example project A EUR 4 m contribution from
partners will be matched by EUR 4 m
EXAMPLE

• Example assumes
• 4 industrial partners hiring 4 new PDs for 4
  years
• 4 academic partners hiring 10 new PhDs for 4 years

27
D. IP Ground Rules (Emiel Staring)
28
The BMM IP Groundrules are (nearly) identical to
CTMM
VSNU, NFU, and Industrial parties have recently
approved the CTMM Groundrules

• IP Groundrules BMM
• Ownership of Foreground IP follows inventorship
• BMM will not own or partially own IP from
  projects
• IP ground rules will be binding for all partners
  and are non-negotiable
• BMM interpretation of Groundrules will be leading
• IP valuation should be part of project agreement
• Paragraph on IP on software or software
  development is not included

Source CTMM IP Workgroup
29
IP Ground rules BMM Protection process
Publication
1
2
3
4
Invention
45 Days review project members
Licensee group
Patent
Commercial use
Internal use
Source CTMM IP Workgroup
30
IP Ground rules BMM Internal Use
Internal use

• Academic Party
• Free non excl In house use of all Foreground IP
  in research and education
• Can License out to third party for research
  purposes (contract needed)
• Value shared between those Academic Parties that
  paid patent cost

• Commercial party
• Free non excl In house use of all Foreground IP
  in research
• Cannot sublicense to third parties
• Pay share in patent cost

Source CTMM IP Workgroup
31
IP Ground rules BMM Commercial Use
Commercial use

• Academic Parties Private parties
• Pay share in patent cost
• Negotiate conditions for license or assignment
• Conditions arms length relative discount
  related to contribution to Project
• Clauses on anti-shelving and patent misuse in
  license agreement
• Revenue of license agreement or assignment 40
  to inventing party, 60 to academic parties,
  unless parties agree on different ratio in
  Project Agreement

Source CTMM IP Workgroup
32
E. Questions
33
Networking eventLectures and poster session